Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2017-02-13
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Etoposide phosphate; Liposomal doxorubicin; Prednisone; Vinblastine; Vincristine

Criteria

INCLUSION CRITERIA:

• Diagnosis of previously untreated stage I or IIA Hodgkin's lymphoma, eligible subtypes

• Nodular sclerosis

• Mixed cellularity

• Classical, not otherwise specified

• Age ≥ 18 years and ≤ 70 years

• Granulocytes ≥ 2 x 10e6/µL

• Platelets ≥ 150 x 10e6/µL

• Bilirubin ≤ 2.5 mg/dL

• Serum creatinine ≤ 2 mg/dL

• Patients > 50 years or those with a history of cardiac disease should have an ejection fraction ≥ 50%

• All scans, X-rays, laboratory tests must be performed within 6 weeks of enrollment

• Pathologic material reviewed at Stanford University

• Evaluation by Stanford Medical Oncology and Radiation Oncology with review at the Hodgkin's Disease Staging Conference

• Written informed consent

EXCLUSION CRITERIA:

• Lymphocytic predominance Hodgkin's disease

• Prior treatment for Hodgkin's disease

• Mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter on a standing posteroanterior chest x-ray

• Any lymph node mass > 10 cm in greatest trans-axial diameter

• Two or more extranodal sites of disease

• Constitutional (B) symptoms present at diagnosis

• Prior or concurrent malignancies within 5 years (EXCEPTION: basal cell carcinoma of the skin)

• Any medical contraindication to the planned treatment, including:

• Pregnant

• Positive antibody test for the human immunodeficiency virus (HIV)